M Chavez-MacGregor1, H Zhao2, M Kroll3, S Fang2, N Zhang2, G N Hortobagyi2, T A Buchholz4, Y-C Shih5, S H Giordano6. 1. Division of Cancer Medicine. 2. Department of Breast Medical Oncology. 3. Section of Benign Hematology. 4. Division of Radiation Oncology. 5. Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, USA. 6. Department of Breast Medical Oncology. Electronic address: sgiordan@mdanderson.org.
Abstract
BACKGROUND: The purpose of this study is to evaluate the risk factors and the prevalence of thromboembolic events (TEEs) in breast cancer patients. PATIENTS AND METHODS: This is a retrospective cohort study using the Surveillance, Epidemiology, and End Results-Medicare database. Breast cancer patients diagnosed from 1992 to 2005 ≥66 years old were identified. International Classification of Diseases, Ninth Revision, and Healthcare Common Procedure Coding System codes were used to identify TEEs within 1 year of the breast cancer diagnosis. Analyses were conducted using descriptive statistics and logistic regression. RESULTS: A total of 89 841 patients were included, of them 2658 (2.96%) developed a TEE. In the multivariable analysis, males had higher risk of a TEE than women [odd ratio (OR) = 1.57; confidence interval (CI) 1.10-2.25] and blacks had higher risk than whites (OR = 1.20; CI 1.04-1.40). Compared with stage I patients, patients with stage II, III and IV had 22%, 39% and 98% increase, respectively, in risk. Placement of central catheters (OR = 2.71; CI 2.43-3.02), chemotherapy treatment (OR = 1.66; CI 1.48-1.86) or treatment with erythropoiesis-stimulating agents (ESAs) (OR = 1.33; CI 1.33-1.52) increase the risk. Other significant predictors included comorbidities, age, receptor status, marital status and year of diagnosis. Similar estimates were seen for pulmonary embolism, deep vein thromboembolism and other TEEs. CONCLUSIONS: In total, 2.96% of patients in this cohort developed a TEE within 1 year from breast cancer diagnosis. Stage, gender, race, use of chemotherapy and ESAs, comorbidities, receptor status and catheter placement were associated with the development of TEEs.
BACKGROUND: The purpose of this study is to evaluate the risk factors and the prevalence of thromboembolic events (TEEs) in breast cancerpatients. PATIENTS AND METHODS: This is a retrospective cohort study using the Surveillance, Epidemiology, and End Results-Medicare database. Breast cancerpatients diagnosed from 1992 to 2005 ≥66 years old were identified. International Classification of Diseases, Ninth Revision, and Healthcare Common Procedure Coding System codes were used to identify TEEs within 1 year of the breast cancer diagnosis. Analyses were conducted using descriptive statistics and logistic regression. RESULTS: A total of 89 841 patients were included, of them 2658 (2.96%) developed a TEE. In the multivariable analysis, males had higher risk of a TEE than women [odd ratio (OR) = 1.57; confidence interval (CI) 1.10-2.25] and blacks had higher risk than whites (OR = 1.20; CI 1.04-1.40). Compared with stage I patients, patients with stage II, III and IV had 22%, 39% and 98% increase, respectively, in risk. Placement of central catheters (OR = 2.71; CI 2.43-3.02), chemotherapy treatment (OR = 1.66; CI 1.48-1.86) or treatment with erythropoiesis-stimulating agents (ESAs) (OR = 1.33; CI 1.33-1.52) increase the risk. Other significant predictors included comorbidities, age, receptor status, marital status and year of diagnosis. Similar estimates were seen for pulmonary embolism, deep vein thromboembolism and other TEEs. CONCLUSIONS: In total, 2.96% of patients in this cohort developed a TEE within 1 year from breast cancer diagnosis. Stage, gender, race, use of chemotherapy and ESAs, comorbidities, receptor status and catheter placement were associated with the development of TEEs.
Authors: M Karthaus; A Kretzschmar; H Kröning; M Biakhov; D Irwin; N Marschner; C Slabber; G Fountzilas; A Garin; N G F Abecasis; W Baronius; G G Steger; T Südhoff; C Giorgetti; P Reichardt Journal: Ann Oncol Date: 2005-11-29 Impact factor: 32.976
Authors: Hans-Martin M B Otten; Joost Mathijssen; Hugo ten Cate; Marcel Soesan; Marijke Inghels; Dick J Richel; Martin H Prins Journal: Arch Intern Med Date: 2004-01-26
Authors: Julia Bohlius; Kurt Schmidlin; Corinne Brillant; Guido Schwarzer; Sven Trelle; Jerome Seidenfeld; Marcel Zwahlen; Michael Clarke; Olaf Weingart; Sabine Kluge; Margaret Piper; Dirk Rades; David P Steensma; Benjamin Djulbegovic; Martin F Fey; Isabelle Ray-Coquard; Mitchell Machtay; Volker Moebus; Gillian Thomas; Michael Untch; Martin Schumacher; Matthias Egger; Andreas Engert Journal: Lancet Date: 2009-05-02 Impact factor: 79.321
Authors: Katarzyna Wrzeszcz; Artur Słomka; Elżbieta Zarychta; Piotr Rhone; Barbara Ruszkowska-Ciastek Journal: J Clin Med Date: 2022-04-25 Impact factor: 4.964
Authors: Jennifer H Jordan; Soe Soe Thwin; Timothy L Lash; Diana S M Buist; Terry S Field; Reina Haque; Pamala A Pawloski; Hans V Petersen; Marianne N Prout; Virginia P Quinn; Marianne Ulcickas Yood; Rebecca A Silliman; Ann M Geiger Journal: Breast Cancer Res Treat Date: 2014-06-18 Impact factor: 4.872
Authors: Volker Moebus; Christian Jackisch; Andreas Schneeweiss; Jens Huober; Hans-Joachim Lueck; Andreas du Bois; Christoph Thomssen; Christian Kurbacher; Walther Kuhn; Ulrike Nitz; Ingo B Runnebaum; Axel Hinke; Rolf Kreienberg; Michael Untch Journal: J Natl Cancer Inst Date: 2013-07-16 Impact factor: 13.506